Our members

Adalid Sciences specializes in the development of lipid nanoparticle (LNP) delivery systems for nucleic acid-based therapeutics, such as mRNA, siRNA, and gene editing tools. By leveraging advanced LNP technology, Adalid aims to enhance the efficacy, safety, and precision targeting of these therapies, improving clinical outcomes while minimizing off-target effects and toxicity. This delivery platform enables the treatment of challenging and currently incurable diseases, and plays a key role in the development of next-generation vaccines and genetic medicines. The company was established in June 2024 as a spin-off from the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences. The team brings decades of expertise in using lipid nanoparticles as delivery systems for nucleic acids and related fields.

Founded in 2018 as a scientific spin-off from IOCB Prague, DIANA Biotechnologies has raised €3.5 million in private investment and became the largest producer of COVID-19 tests in Czechia, delivering over 6 million PCR tests to date. The name DIANA stands for DNA-linked Inhibitor Antibody Assay — a method that can precisely detect a variety of diseases.
It targets pathogens and significantly amplifies the evidence of their presence in biological samples. Today, DIANA Biotechnologies provides a wide range of PCR products to diagnostic and academic labs, including custom oligonucleotide synthesis. Their technology also enables the efficient and sensitive development of monoclonal antibodies, and they offer drug discovery services featuring their proprietary DIANA Kinase panels. The company has earned major recognition, including awards like Deloitte Fast 50 and EY Entrepreneur of the Year